Veracyte (VCYT) Revenue (2012 - 2026)

Veracyte has disclosed Revenue across 15 years of filings, most recently posting $139.1 million for Q1 2026.

• Revenue for Q1 2026 came in at $139.1 million, up 21.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $541.7 million (up 16.91% YoY), and the FY2025 annual result was $517.1 million, up 16.01% from the prior year.
• Revenue came in at $139.1 million for Q1 2026 at Veracyte, down from $140.6 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $140.6 million in Q4 2025 to a low of $67.8 million in Q1 2022.
• The 5-year median for Revenue is $98.2 million (2023), against an average of $103.5 million.
• Across the five-year window, Revenue surged 84.68% in 2022 and gained 13.75% in 2025, its largest moves.
• Veracyte's Revenue stood at $80.3 million in 2022, then grew by 22.29% to $98.2 million in 2023, then rose by 20.81% to $118.6 million in 2024, then climbed by 18.55% to $140.6 million in 2025, then fell by 1.11% to $139.1 million in 2026.
• The last three Revenue figures came in at $139.1 million (Q1 2026), $140.6 million (Q4 2025), and $131.9 million (Q3 2025), per Business Quant data.